NICE has recommended a new first-line treatment for adults with advanced bladder cancer, marking a significant breakthrough for patients facing this devastating disease.

Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority ...

Seven other digital technologies - Beat Better, Datos Health, Get Ready, Luscii vitals, Pumping Marvellous Cardiac Rehab Platform, R Plus Health and Sword Move - require more research before they can ...

Women, older people and Black people less likely to receive an SGLT-2 inhibitor prescription for type 2 diabetes ...

Hundreds with rare inherited eye disease to benefit after NICE recommends treatment NICE recommends idebenone for Leber's hereditary optic neuropathy following clinical evidence of vision improvement.

In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (also called Brineura and made by BioMarin) for routine NHS use in treating neuronal ceroid ...

NICE approves first immunotherapy combination for endometrial cancer Around 2,100 people with advanced womb cancer are set to benefit from a groundbreaking new treatment option, following our ...

Evidence-based recommendations on ruxolitinib cream (Opzelura) for treating non-segmental vitiligo in people 12 years and over ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...

Ruxolitinib cream (Opzelura, Incyte) is indicated for 'the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age'.

The National Institute for Health and Care Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Percutaneous thrombectomy for intermediate-risk or high ...